Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah™ (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice

Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah™ (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice

Aug 30, 2017
Source URL: https://qa1.novartis.us/news/media-releases/novartis-receives-first-ever-fda-approval-car-t-cell-therapy-kymriahtm-tisagenlecleucel-ctl019-children-and-young-adults-b-cell-all-refractory-or-has-relapsed-least-twice-0

List of links present in page
  1. https://qa1.novartis.us/news/media-releases/novartis-receives-first-ever-fda-approval-car-t-cell-therapy-kymriahtm-tisagenlecleucel-ctl019-children-and-young-adults-b-cell-all-refractory-or-has-relapsed-least-twice-0